Clinical Trial Update: A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Pacemaker implantation versus Percutaneous Transluminal Septal Ablation for hypertrophic cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Hypertrophic Cardiomyopathy | Phase 2 | Status: COMPLETED